Surratt Christopher K, Adams Wendy R
Division of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA 15282, USA.
Curr Top Med Chem. 2005;5(3):315-24. doi: 10.2174/1568026053544533.
As a whole, the G protein-coupled receptor (GPCR) superfamily displays no overall sequence homology. Nevertheless, enough short sequences and even individual amino acid residues are shared by these receptors to afford a common three-dimensional structure and a similar signal transduction mechanism. Some of these sequence commonalities, or structural motifs, are dedicated to preserving receptor infrastructure, while others are critical to agonist-mediated signaling. Certain structural motifs common to GPCRs and other signal transducing integral membrane proteins are present in the conventional opioid receptors, although several of the motifs are not well characterized in this receptor family. Here we focus on six structural motifs found in the mu, delta and kappa opioid receptors as well as the opioid like receptor ORL-1. The motifs are discussed in terms of their dynamic roles in the signaling mechanism documented for several Class A GPCRs including the opioid receptors. Clarification of the roles of GPCR structural motifs provides a blueprint for structure-function studies on newly discovered or recently cloned receptors in the superfamily. Characterization of these motifs in the opioid receptors should enhance understanding of what makes an opioid ligand a full, partial or inverse agonist or antagonist at a given receptor, possibly leading to rational design of therapeutics useful for combating opiate dependence or for pain management.
总体而言,G蛋白偶联受体(GPCR)超家族不存在整体序列同源性。然而,这些受体共享足够多的短序列甚至单个氨基酸残基,以形成共同的三维结构和相似的信号转导机制。其中一些序列共性或结构基序致力于维持受体的结构基础,而其他一些则对激动剂介导的信号传导至关重要。传统阿片受体中存在一些GPCR和其他信号转导整合膜蛋白共有的结构基序,尽管其中一些基序在该受体家族中的特征并不明确。在此,我们聚焦于在μ、δ和κ阿片受体以及类阿片受体ORL-1中发现的六个结构基序。将根据这些基序在包括阿片受体在内的几种A类GPCR的信号传导机制中的动态作用进行讨论。阐明GPCR结构基序的作用为该超家族中新发现或最近克隆的受体的结构-功能研究提供了蓝图。对阿片受体中这些基序的表征应能增进对使阿片配体在给定受体上成为完全激动剂、部分激动剂或反向激动剂或拮抗剂的因素的理解,这可能会引导用于对抗阿片类药物依赖或疼痛管理的治疗药物的合理设计。